May 26, 2021
Immutep Granted Chinese Patent for Eftilagimod Alpha in Chemo-Immunotherapy Combination
May 24, 2021
Immutep to Present at the Jefferies Virtual Healthcare Conference
May 20, 2021
Immutep Announces Publication of TACTI-002 and INSIGHT-004 Abstracts for ASCO 2021 Annual Meeting
May 06, 2021
Immutep Operational Update
Apr 27, 2021
Immutep To Announce New TACTI-002 and INSIGHT-004 Data in Poster Presentations and Discussion at the ASCO 2021 Annual Meeting
Apr 18, 2021
Immutep Quarterly Activities Report
Apr 16, 2021
Immutep Receives A$1,155,055 R&D Tax Incentive
Apr 07, 2021
Immutep Achieves Fast Track Designation From US FDA For Efti, A Soluble Lag-3 Protein, In First Line Recurrent/Metastatic Head & Neck Cancer
Apr 06, 2021
Immutep Announces European Patent Grant For LAG525 Antibody In Combination Therapy
Mar 17, 2021
Immutep To Participate In A Fireside Chat At The Inaugural M Vest And Maxim Group Emerging Growth Virtual Conference
Mar 16, 2021
Immutep Enters Second Collaboration with MSD for a New Randomised Phase IIB Trial in Head and Neck Cancer
Mar 09, 2021
Immutep Secures Second United States Patent Grant For Eftilagimod Alpha In Combination With A PD-1 Pathway Inhibitor
Mar 05, 2021
Immutep Expands Part B of TACTI-002 Study
Jan 26, 2021
Immutep Announces Advancement Of Phase II Trial For Eftilagimod Alpha In Covid-19 Patients To Randomised Portion Of The Study
Jan 21, 2021
